阿尔茨海默病中的PAR-1:病理生理学见解和机械学视角
Neha1, Snehashis Mandal2, Vipual Sharma2
1Department of Pharmacy Practice, ISF College of Pharmacy, Moga, 142001, India.
Current medical science
|March 5, 2026
概括
蛋白酶激活受体-1 (PAR-1) 在阿尔茨海默病 (AD) 中具有双重作用,加剧病理,同时也提供神经保护. 抑制PAR-1在阿尔茨海默病的临床前模型中显示出治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默氏病 (AD) 是一种神经退行性疾病,其特征是粉样蛋白β (Aβ) 斑块,神经炎症,病理和突触功能障碍.
- 由血栓激素激活的G蛋白结合受体 (GPCR) 蛋白酶激活受体-1 (PAR-1) 影响AD的发病.
- PAR-1在大脑中表现出复杂的作用,影响神经炎症,Aβ积累,突触可塑性和血脑屏障 (BBB) 完整性.
研究的目的:
- 审查目前对阿尔茨海默病中PAR-1的机制的理解.
- 要突出PAR-1在Aβ沉积,神经炎症和病理方面的参与.
- 讨论治疗策略和挑战,以针对AD的PAR-1.
主要方法:
- 关于阿尔茨海默病中PAR-1的临床前研究和现有研究的文献综述.
- 在AD病理学背景下分析PAR-1的信号通路和下游影响.
- 检查PAR-1在加剧和潜在地保护AD进展中的双重作用.
主要成果:
- 在临床前的AD模型中,PAR-1激活会加剧神经炎症和Aβ病理.
- 抑制PAR-1已证明在挽救认知缺陷和减少Aβ负担方面具有有效性.
- PAR-1有助于陶过酸化,神经纤维状的形成,以及增加BBB的透性,恶化神经退行.
结论:
- 由于其多方面的作用,PAR-1在阿尔茨海默氏症中具有复杂的治疗标.
- 临床前证据支持PAR-1抑制作为AD治疗的潜在策略.
- 需要进一步的研究和临床试验来探索PAR-1调制,包括重新利用现有的抑制剂,用于AD治疗.
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Amyloid Fibrils
12.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.4K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
2.3K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.3K


